Residency · Residency · Medical Genetics Genomics

Neurodevelopmental Disorders: Genetic Architecture and Testing Strategy

Introduction

Neurodevelopmental disorders (NDDs) encompass a broad group of conditions characterized by impairments in cognition, communication, behavior, and/or motor function arising during the developmental period. These include intellectual disability (ID), autism spectrum disorder (ASD), global developmental delay (GDD), and related conditions. Collectively, NDDs affect 3-5% of children. Advances in genomic technologies have revealed that the majority have a significant genetic component, with a molecular diagnosis achievable in 30-50% of cases using current testing strategies.

Genetic Architecture

De Novo Variants

De novo mutations account for the majority of genetic causes in severe NDD. An estimated 60-80% of pathogenic variants in sporadic severe ID arise de novo. Point mutations, indels, and structural variants all contribute to this category.

Copy Number Variants (CNVs)

Chromosomal microarray detects pathogenic CNVs in approximately 15-20% of individuals with unexplained NDD. Recurrent CNVs are frequently mediated by segmental duplications through nonallelic homologous recombination. Key examples include 16p11.2 deletion/duplication, 1q21.1, 15q11.2-q13, and 22q11.2 deletion syndromes. Variable expressivity and incomplete penetrance are common features of pathogenic CNVs.

Single Gene Disorders

Over 1,500 genes have been associated with intellectual disability. Key functional categories include chromatin remodeling, synaptic function, mTOR/RAS-MAPK signaling, and transcription factors. X-linked intellectual disability alone involves over 150 genes on the X chromosome, including FMR1, MECP2, and ARX.

Oligogenic and Polygenic Models

Milder NDD and ASD may involve polygenic risk from common variants. The two-hit model proposes that some patients carry two or more rare variants contributing additively to phenotype. Common variant polygenic scores are increasingly studied for ASD but are not yet clinically actionable.

Key Genetic Syndromes

Fragile X Syndrome

Fragile X syndrome results from a CGG repeat expansion in FMR1 (more than 200 repeats constitutes a full mutation with methylation). It is the most common inherited cause of intellectual disability, affecting approximately 1 in 4,000 males. Characteristic features include a long face, prominent ears, macroorchidism, and behavioral features including anxiety and social avoidance.

Rett Syndrome

Rett syndrome is caused by MECP2 mutations and predominantly affects females. After normal early development, regression occurs at 6-18 months with stereotypic hand movements, loss of purposeful hand use, and gait abnormalities.

Angelman Syndrome

Angelman syndrome results from loss of maternal UBE3A expression through deletion, UPD, imprinting defect, or point mutation. It presents with severe ID, absent speech, seizures, happy demeanor, and ataxic gait.

SYNGAP1-Related Disorder

De novo loss-of-function variants in SYNGAP1 cause ID, epilepsy (often eyelid myoclonia with absences), and ASD features. This disorder is increasingly recognized through exome sequencing.

Other High-Yield Genes

Additional frequently identified NDD genes include DYRK1A, ADNP, KAT6A, ARID1B, KDM5C, DDX3X, and PURA, many of which were discovered through large-scale exome sequencing studies.

Diagnostic Testing Strategy

First-Tier Testing

Chromosomal microarray (CMA) is the standard first-line genetic test for unexplained ID/GDD/ASD, detecting pathogenic CNVs in approximately 15-20% of cases. It does not detect balanced rearrangements or point mutations. Fragile X testing via FMR1 CGG repeat analysis should be performed concurrently, especially in males with ID.

Second-Tier Testing

Exome sequencing (ES) achieves a diagnostic yield of 25-40% after negative CMA. Trio analysis (proband plus both parents) is preferred to identify de novo variants and is increasingly used as a first-line test alongside or instead of CMA in some centers.

Emerging Approaches

Genome sequencing (GS) can detect SNVs, CNVs, structural variants, and repeat expansions in a single test. Optical genome mapping identifies complex structural rearrangements. Episignature analysis uses DNA methylation profiling to confirm variants of uncertain significance in chromatin-related genes. RNA sequencing can identify variants affecting splicing.

When Testing Is Non-Diagnostic

Periodic reanalysis of exome or genome data every 1-2 years is recommended as new genes are discovered. A metabolic workup should be considered if not previously performed. Brain MRI and EEG provide additional phenotypic characterization. Research-based testing and matchmaking platforms such as GeneMatcher and MyGene2 can facilitate novel gene discovery.

Yield by Testing Modality

Counseling Considerations

Recurrence risk depends on the mechanism: de novo variants carry low risk (approximately 1%), while inherited variants may confer up to 50% risk for autosomal dominant, 25% for autosomal recessive, and variable risk for X-linked conditions. Gonadal mosaicism means the recurrence risk for apparently de novo variants is approximately 1-2% but can be higher for specific genes. Family-centered communication is essential, as a diagnosis provides explanation, connects families to resources, and enables reproductive planning. Many families report a diagnostic odyssey averaging 5-7 years to diagnosis; genomic testing shortens this significantly.

Clinical Pearls

Chromosomal microarray remains the recommended first-line genetic test for unexplained ID/GDD/ASD per ACMG guidelines, though exome and genome sequencing are increasingly used as first-line tests. Trio exome sequencing dramatically improves de novo variant detection and interpretability compared to proband-only testing. A molecular diagnosis changes management in approximately 30-40% of diagnosed cases through medication changes, surveillance recommendations, or targeted therapies. Periodic reanalysis of negative genomic data is essential, as approximately 10-15% of previously unsolved cases receive a diagnosis upon reanalysis with updated gene-disease knowledge.

References

1. Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21(11):2413-2421.
2. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519(7542):223-228.
3. Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the ACMG. Genet Med. 2021;23(11):2029-2037.
4. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nat Rev Genet. 2018;19(5):253-268.

Read this lecture as Markdown